Fri, Sep 19, 2014, 12:51 AM EDT - U.S. Markets open in 8 hrs 39 mins

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • simp08801 simp08801 Mar 28, 2013 7:31 AM Flag

    JMP Price Target Now $50

    "During our meeting, she relayed anecdotal stories about the remarkable
    benefits of eteplirsen in many of the 12 subjects in the eteplirsen study including many
    that cannot be captured by the six-minute walk test in young children, including balance,
    fine motor skills, higher energy, new motor skills, as well as cardiac and cognitive
    benefits. ... Our meeting left us more optimistic regarding the possibility of an accelerated approval
    based on medical urgency, safety profile, FDA mandate to speed access to lifesaving
    therapies and likelihood that the FDA has data from competitor Prosensa's first placebo
    controlled study ... we assign a one-third chance of an accelerated
    approval ahead of meeting minutes which we expect by the end of April ... We believe shares of
    SRPT are a good investment regardless of the outcome next month because we believe
    the drug will ultimately be approved."

    IMO, most important words:

    "MANY OF THE 12 SUBJECTS"

    this bodes quite well for the impending test results

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SRPT
22.53-0.41(-1.79%)Sep 18 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT